InsiderTrades

Form 4 for MRNA Moderna

Accepted 2024-08-29 00:00:00 ET · period of report 2024-08-27 · accession 0001127602-24-023162 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X Filed Traded Ticker Insider Title Type Price Qty Owned ΔOwn Value
DM 2024-08-29 2024-08-27 MRNA Mock James M CFO M - OptEx — +2,652 9,921 +36% —
D 2024-08-29 2024-08-28 MRNA Mock James M CFO S - Sale+OE $79.39 -1,321 8,600 -13% -$104.9K
DM 2024-08-29 2024-08-27 MRNA Mock James M CFO M - OptEx $0.00 -2,652 2,652 -50% $0

Purchase Sale Sale after option exercise All abbreviations

Every reported transaction

#TableSecurityDateCodeA/DSharesPriceOwned afterOwnExercise / expiryUnderlyingFootnotes
1 Common Common Stock 2024-08-27 M A 1,326 — 8,595 D — — (F1) Performance stock units convert into common stock on a one-for-one basis.
2 Common Common Stock 2024-08-28 S D 1,321 $79.39 8,600 D — —
3 Common Common Stock 2024-08-27 M A 1,326 — 9,921 D — — (F2) Restricted stock units convert into common stock on a one-for-one basis.
4 Derivative Performance Stock Units 2024-08-27 M D 1,326 $0.00 2,652 D — · — to — 1,326 Common Stock (F1) Performance stock units convert into common stock on a one-for-one basis. (F4) 25% of the shares subject to this performance stock unit award vested on May 31, 2024 upon determination of achievement of the performance criteria, with the remainder vesting in three (3) equal installments on August 27, 2024, November 27, 2024 and February 27, 2025.
5 Derivative Restricted Stock Units 2024-08-27 M D 1,326 $0.00 2,652 D — · — to — 1,326 Common Stock (F2) Restricted stock units convert into common stock on a one-for-one basis. (F5) 25% of the shares subject to this restricted stock unit award vested on May 27, 2024 with the remainder vesting in three (3) equal quarterly installments thereafter.